IL6 and cancer: For instance, Caseinolytic protease P (ClpP), Ets-like protein 1 (Elk-1), the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway, the polo-box domain of polo-like kinase 1 (PLK1-PBD) and interleukin-6 (IL6) modulate different processes (e.g., the degradation of misfolded proteins, gene regulation in response to extracellular signals, immune escape, proliferation, inflammation) linked to cancer onset and progression or acute myeloid leukemia (AML) and represent only a few possible targets [107,108,109,110,111].